{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:19Z","timestamp":1791414619436,"version":"4.3.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00280-011-1661-5","type":"journal-article","created":{"date-parts":[[2011,5,17]],"date-time":"2011-05-17T15:06:26Z","timestamp":1305644786000},"page":"1611-1617","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency"],"prefix":"10.1007","volume":"68","author":[{"given":"Maurice C.","family":"van Staveren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Theeuwes-Oonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 B. P.","family":"van Kuilenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Gerard","family":"Maring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,18]]},"reference":[{"issue":"10","key":"1661_CR1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","volume":"6","author":"HM Pinedo","year":"1988","unstructured":"Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6(10):1653\u20131664","journal-title":"J Clin Oncol"},{"key":"1661_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diassio","year":"1989","unstructured":"Diassio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Phamacokinet 16:215\u2013237","journal-title":"Clin Phamacokinet"},{"issue":"11","key":"1661_CR3","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O et al (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients with advanced colorectal cancer. J Clin Oncol 12(11):2248\u20132253","journal-title":"J Clin Oncol"},{"key":"1661_CR4","first-page":"2899","volume":"52","author":"RA Flemming","year":"1992","unstructured":"Flemming RA, Milano G et al (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899\u20132902","journal-title":"Cancer Res"},{"key":"1661_CR5","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Song R (1990) Relation between dihydropyrimidine dehydrogenase and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil bij protracted continuous infusion. Cancer Res 50:197\u2013201","journal-title":"Cancer Res"},{"key":"1661_CR6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6600208","volume":"86","author":"JG Maring","year":"2002","unstructured":"Maring JG, van Kuilenburg ABP, Haasjes J et al (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86:1028\u20131033","journal-title":"Br J Cancer"},{"key":"1661_CR7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/15257770802145009","volume":"27","author":"ABP Kuilenburg van","year":"2008","unstructured":"van Kuilenburg ABP, Maring JG, Schalhom A et al (2008) Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14\u00a0+\u00a01G>A mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids 27:692\u2013698","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1661_CR8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00280-005-0139-8","volume":"58","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, DAhan L, Evrard A, Boyer JC, Richard K, Dales JP, Durand A, Milano G, Seitz JF, Lacarelle B (2006) Toxic death-case after capecitabine\u00a0+\u00a0oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol 58:272\u2013275","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"1661_CR9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tips.2007.09.009","volume":"28","author":"C Mercier","year":"2007","unstructured":"Mercier C, Ciccolini J (2007) Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 28(12):597\u2013598","journal-title":"Trends Pharmacol Sci"},{"key":"1661_CR10","first-page":"4705","volume":"6","author":"ABP Kuilenburg van","year":"2006","unstructured":"van Kuilenburg ABP, Haasjes J, Richel D et al (2006) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6:4705\u20134712","journal-title":"Clin Cancer Res"},{"key":"1661_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","volume":"101","author":"ABP Kuilenburg van","year":"2002","unstructured":"van Kuilenburg ABP, Meinsma R, Zoetekouw L, van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-FU due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14\u00a0+\u00a01G>A mutation. Int J Canc 101:253\u2013258","journal-title":"Int J Canc"},{"key":"1661_CR12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E (2007) 5-Fluorouracil-related toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271\u2013282","journal-title":"Cancer Lett"},{"key":"1661_CR13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00280-010-1282-4","volume":"67","author":"CG Yang","year":"2010","unstructured":"Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C et al (2010) DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 67:49\u201356","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1661_CR14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200210000-00007","volume":"12","author":"ABP Kuilenburg van","year":"2002","unstructured":"van Kuilenburg ABP, Meinsma R, Zoetekouw L et al (2002) High prevalence of the IVS14\u00a0+\u00a01G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12(7):555\u2013558","journal-title":"Pharmacogenetics"},{"key":"1661_CR15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB (2006) The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res 12:549\u2013555","journal-title":"Clin Cancer Res"},{"key":"1661_CR16","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","volume":"10","author":"LK Mattison","year":"2004","unstructured":"Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10:2652\u20132658","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1661_CR17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2125.2005.02472.x","volume":"60","author":"S Ito","year":"2005","unstructured":"Ito S, Kawamura T, Inada M et al (2005) Physiologically modelling of the three-step metabolism of pyrimidine using 13C-uracil as an in vivo probe. British J of Clinical Pharmacol 60(6):584\u2013593","journal-title":"British J of Clinical Pharmacol"},{"issue":"12","key":"1661_CR18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0378-4347(99)00446-6","volume":"736","author":"J Escoriaza","year":"1999","unstructured":"Escoriaza J, Aldaz A, Calvo E et al (1999) Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. Application to clinical pharmacokineticstudies. J Chromatogr B Biomed Sci Appl 736(12):97\u2013102","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"4","key":"1661_CR19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1177\/147323001003800413","volume":"38","author":"MH Kristensen","year":"2010","unstructured":"Kristensen MH, Pedersen P, Mejer J (2010) The value of dihydrouracil\/uracil plasma ratios in predicting 5-Fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 38(4):1313\u20131323","journal-title":"J Int Med Res"},{"issue":"4","key":"1661_CR20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clpt.2006.06.007","volume":"80","author":"G Bocci","year":"2006","unstructured":"Bocci G, Barbara C, Vannozzi F, Di Paolo A, Melosi A, Barsanti G, Allegrini G, Falcone A, Del Tacca M, Danesi R (2006) A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther 80(4):384\u2013395","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1661_CR21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2125.2008.03307.x","volume":"67","author":"G Bocci","year":"2010","unstructured":"Bocci G, Di Paolo A, Barbara C, Masi G, Fornaro L et al (2010) Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. Br J of Clin Pharmacol 67(1):132\u2013134","journal-title":"Br J of Clin Pharmacol"},{"issue":"5","key":"1661_CR22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","volume":"28","author":"J Ciccoline","year":"2006","unstructured":"Ciccoline J, Mercier C, Evrard A, Boyer JC, Duffaud F, Dhan L, Richard K, Blanquicett C, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B (2006) A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 28(5):678\u2013685","journal-title":"Ther Drug Monit"},{"key":"1661_CR23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0378-4347(99)00528-9","volume":"738","author":"B Daoqin","year":"2000","unstructured":"Daoqin B, Anderson LW, Shapiro J, Shapiro A, Grem JL, Takimoto CH (2000) Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase. J Chromatorgr B 738:249\u2013258","journal-title":"J Chromatorgr B"},{"issue":"6","key":"1661_CR24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.patbio.2008.05.001","volume":"57","author":"RB Fredj","year":"2009","unstructured":"Fredj RB, Gross E, Ahmed SB, Hassine H, Saguem S (2009) The dihydrouracil\/uracil ratio in plasma, clinical and genetic analysis or screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil. Pathol Biol 57(6):470\u2013476","journal-title":"Pathol Biol"},{"key":"1661_CR25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2710.2004.00569.x","volume":"29","author":"J Ciccolini","year":"2004","unstructured":"Ciccolini J, Mecier C, Blanchon MF, Favre R, Durand A, Lacarelle B (2004) A simple and rapid high-performance liquid chromatographic (HPLC) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 29:307\u2013315","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1661_CR26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000099984","volume":"53","author":"ZW Zhou","year":"2007","unstructured":"Zhou ZW, Wang GQ, de Wan S, Lu ZH, Chen YB, Li S, Chen G, Pan ZZ (2007) The dihydrouracil\/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 53(2):127\u2013131","journal-title":"Chemotherapy"},{"issue":"4","key":"1661_CR27","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","volume":"17","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M, Gu\u00e9rin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17(4):1105\u20131110","journal-title":"J Clin Oncol"},{"key":"1661_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","volume":"46","author":"ABP Kuilenburg van","year":"2000","unstructured":"van Kuilenburg ABP, van Lenthe H, Tromp A, Veltman PCJ, van Gennip AH (2000) Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 46:9\u201317","journal-title":"Clin Chem"},{"issue":"1","key":"1661_CR29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00007691-200502000-00006","volume":"27","author":"JG Maring","year":"2005","unstructured":"Maring JG, Schouten L, Greijdanus B, de Vries EG, Uges DR (2005) A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5, 6-dihydrofluorouracil in plasma. Ther Drug Monit 27(1):25\u201330","journal-title":"Ther Drug Monit"},{"issue":"2","key":"1661_CR30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41(2):67\u201376","journal-title":"Drug Metab Rev"},{"issue":"2","key":"1661_CR31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2215\/CJN.03960609","volume":"5","author":"C Aymanns","year":"2010","unstructured":"Aymanns C, Keller F, Maus S, Hartmann B et al (2010) Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 5(2):314\u2013327","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1661_CR32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1665-2681(19)31651-5","volume":"9","author":"G Ramadori","year":"2010","unstructured":"Ramadori G, Cameron S (2010) Effects of systemic chemotherapy on the liver. Ann Hepatol 9(2):133\u2013143","journal-title":"Ann Hepatol"},{"issue":"2","key":"1661_CR33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-002-0535-2","volume":"51","author":"JG Maring","year":"2003","unstructured":"Maring JG, Piersma H, van Dalen A, Groen HJ, Uges DR, De Vries EG (2003) Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. Cancer Chemother Pharmacol 51(2):167\u2013173","journal-title":"Cancer Chemother Pharmacol"},{"key":"1661_CR34","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R","volume":"63","author":"MJ O\u2019Connell","year":"1989","unstructured":"O\u2019Connell MJ (1989) A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic\/North Central Cancer Treatment Group study. Cancer 63:1026\u20131030","journal-title":"Cancer"},{"key":"1661_CR35","first-page":"1897","volume":"21","author":"ML Rothenberg","year":"2003","unstructured":"Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK et al (2003) Superiority of oxaliplatin and fluorouracil and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinoctecan and fluorouracil-leucovorin: interi results of a phase III trial. J Clin Oncol 21:1897\u20131905","journal-title":"J Clin Oncol"},{"key":"1661_CR36","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.1997.15.5.1897","volume":"15","author":"DJ Stewart","year":"1997","unstructured":"Stewart DJ, Evans WK, Shepard FA, Wilson KS, Pritchard KI, Trudeau MF et al (1997) Cyclofosfamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 15:1897\u20131905","journal-title":"J Clin Oncol"},{"key":"1661_CR37","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1200\/JCO.2000.18.17.3125","volume":"18","author":"D Amadori","year":"2000","unstructured":"Amadori D, Nanni O, Marangolo M, Pacini R, Ravaioli A, Rossi A et al (2000) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomised multicenter study. J Clin Oncol 18:3125\u20133134","journal-title":"J Clin Oncol"},{"issue":"2","key":"1661_CR38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","volume":"12","author":"K Mattison","year":"2006","unstructured":"Mattison K, Fourie J, Hirao Y, Koga T et al (2006) The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C] dihydrouracil. Clin Cancer Res 12(2):549\u2013555","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1661-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T05:27:09Z","timestamp":1592544429000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1661-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,18]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1661-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,18]]}}}